Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
122.77B
Market cap122.77B
Price-Earnings ratio
17.27
Price-Earnings ratio17.27
Dividend yield
4.17%
Dividend yield4.17%
Average volume
13.95M
Average volume13.95M
High today
$60.40
High today$60.40
Low today
$59.24
Low today$59.24
Open price
$59.85
Open price$59.85
Volume
13.33M
Volume13.33M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 122.77B, Bristol-Myers Squibb(BMY) trades at $60.35. The stock has a price-to-earnings ratio of 17.27 and currently yields dividends of 4.2%.

As of 2026-02-20, Bristol-Myers Squibb(BMY) stock has fluctuated between $59.24 and $60.40. The current price stands at $60.35, placing the stock +1.9% above today's low and -0.1% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 13.33M, compared to an average daily volume of 13.95M.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

BMY News

Simply Wall St 2d
We Like Bristol-Myers Squibb's Earnings For More Than Just Statutory Profit

Bristol-Myers Squibb Company ( ) announced a healthy earnings result recently, and the market rewarded it with a strong uplift in the stock price. This reaction...

We Like Bristol-Myers Squibb's Earnings For More Than Just Statutory Profit
TipRanks 3d
Balanced Risk-Reward Keeps Bristol-Myers Squibb Rated Hold as CELMoD Franchise Awaits Key Iberdomide Data

William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating today. Matt Phipps has given his Hold rating due to a...

Simply Wall St 3d
What Bristol-Myers Squibb's Earnings Rebound and Completed Buybacks Mean For Shareholders

In early February 2026, Bristol-Myers Squibb reported fourth-quarter 2025 revenue of US$12,502 million and net income of US$1,087 million, while confirming comp...

What Bristol-Myers Squibb's Earnings Rebound and Completed Buybacks Mean For Shareholders

Analyst ratings

57%

of 30 ratings
Buy
40%
Hold
56.7%
Sell
3.3%

More BMY News

Simply Wall St 5d
Assessing Bristol-Myers Squibb Valuation After Earnings Beat And Newer Drug Growth

Bristol-Myers Squibb (BMY) is back in focus after reporting fourth quarter and full year 2025 results that beat consensus expectations, with newer drugs and cos...

Assessing Bristol-Myers Squibb Valuation After Earnings Beat And Newer Drug Growth
TipRanks 7d
BMY-Backed Milvexian Stroke Trial Moves Forward, Keeping Upside Optionality Alive

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. The LIBREXIA-STROKE study tests milvexian in people who recently had an...

TipRanks 7d
Bristol-Myers Squibb Expands Real-World MDS Footprint in Asia With New Registry Study

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. The Asia Myelodysplastic Syndrome (MDS) Registry is an observational st...

Simply Wall St 7d
Bristol-Myers Squibb Earnings Strength And Pipeline Shape Future Valuation

Bristol-Myers Squibb (NYSE:BMY) reported strong fourth quarter earnings, supported by a growth portfolio that includes several products now generating more than...

Bristol-Myers Squibb Earnings Strength And Pipeline Shape Future Valuation

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.